JP5042861B2 - 結晶性1H−イミダゾ[4,5−b]ピリジン−5−アミン,7−[5−[(シクロヘキシルメチルアミノ)−メチル]−1H−インドール−2−イル]−2−メチル,硫酸塩(1:1),三水和物およびその医薬的使用 - Google Patents
結晶性1H−イミダゾ[4,5−b]ピリジン−5−アミン,7−[5−[(シクロヘキシルメチルアミノ)−メチル]−1H−インドール−2−イル]−2−メチル,硫酸塩(1:1),三水和物およびその医薬的使用 Download PDFInfo
- Publication number
- JP5042861B2 JP5042861B2 JP2007554170A JP2007554170A JP5042861B2 JP 5042861 B2 JP5042861 B2 JP 5042861B2 JP 2007554170 A JP2007554170 A JP 2007554170A JP 2007554170 A JP2007554170 A JP 2007554170A JP 5042861 B2 JP5042861 B2 JP 5042861B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- crystalline
- indol
- imidazo
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- YRJLNTNYWZBQTF-UHFFFAOYSA-N Cc([nH]c1nc(N)c2)nc1c2-c1cc(cc(CN(C)C2CCCCC2)cc2)c2[nH]1 Chemical compound Cc([nH]c1nc(N)c2)nc1c2-c1cc(cc(CN(C)C2CCCCC2)cc2)c2[nH]1 YRJLNTNYWZBQTF-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N C1CCCCC1 Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
元素分析: E6070の炭素、水素、窒素、および硫黄含有量を、Quantitative Technologies、Inc.(QTI)、Whitehouse NJ、USA. で測定した。C、H、およびNを、2400 パーキン-エルマーCHN元素分析計を用いて燃焼分析により測定した。硫黄含量を、燃焼分析を行い、過塩素酸バリウム滴定を行って測定した。QTIで測定したC、H、N、およびSの元素組成値のパーセントは、E6070の分子式C23H36N6O7Sに一致する。該実験値は全て、理論値の±0.3%内であった。該理論値および実験値はともに、該薬物分子に1つの硫酸分子および3つ水分子を足したものから成る。
N.T.: 試験なし
*: 少量の試料を上記測定に使用した。
Claims (10)
- 1H−イミダゾ[4,5−b]ピリジン−5−アミン,7−[5−[(シクロヘキシルメチルアミノ)−メチル]−1H−インドール−2−イル]−2−メチル,硫酸塩(1:1),三水和物結晶。
- 粉末X−線回折パターン中に、8.3±0.2°2θ、10.1±0.2°2θ、14.3±0.2°2θ、15.3±0.2°2θ、および18.1±0.2°2θからなる群から選ばれる、少なくとも2つのピークを有することを特徴とする、請求項1の1H−イミダゾ[4,5−b]ピリジン−5−アミン,7−[5−[(シクロヘキシルメチルアミノ)−メチル]−1H−インドール−2−イル]−2−メチル,硫酸塩(1:1),三水和物結晶。
- 単斜晶系結晶系でP21/n空間群を有する、請求項1の1H−イミダゾ[4,5−b]ピリジン−5−アミン,7−[5−[(シクロヘキシルメチルアミノ)−メチル]−1H−インドール−2−イル]−2−メチル,硫酸塩(1:1),三水和物結晶。
- 結晶格子パラメーター:
a=16.915(3)Å
b=12.384(2)Å
c=12.554(2)Å
β=97.089(8)°
V=2609.7(9)Å3
およびZ値=4を有することを特徴とする、請求項1の1H−イミダゾ[4,5−b]ピリジン−5−アミン,7−[5−[(シクロヘキシルメチルアミノ)−メチル]−1H−インドール−2−イル]−2−メチル,硫酸塩(1:1),三水和物結晶。 - 固体13C NMRスペクトル中に、121.9±0.3ppm;126.2±0.3ppm;128.3±0.3ppm;131.7±0.3ppm;138.8±0.3ppm;146.9±0.3ppm;152.3±0.3ppm;および158.0±0.3ppmからなる群から選ばれる、少なくとも2つのピークを有することを特徴とする、請求項1の1H−イミダゾ[4,5−b]ピリジン−5−アミン,7−[5−[(シクロヘキシルメチルアミノ)−メチル]−1H−インドール−2−イル]−2−メチル,硫酸塩(1:1),三水和物結晶。
- ニート試料の赤外線スペクトル中に、1656、1620、1549、1136、1085、および1033cm−1からなる群から選ばれる、少なくとも2つの吸収バンドを有することを特徴とする、請求項1の1H−イミダゾ[4,5−b]ピリジン−5−アミン,7−[5−[(シクロヘキシルメチルアミノ)−メチル]−1H−インドール−2−イル]−2−メチル,硫酸塩(1:1),三水和物結晶。
- 1H−イミダゾ[4,5−b]ピリジン−5−アミン,7−[5−[(シクロヘキシルメチルアミノ)−メチル]−1H−インドール−2−イル]−2−メチルを水に懸濁して、水性懸濁液を得る工程、
該水性懸濁液に、その内部温度を25℃より低く維持しながら、H2SO4を加えて溶液を調製する工程、
該溶液を適宜ろ過する工程、および
1H−イミダゾ[4,5−b]ピリジン−5−アミン,7−[5−[(シクロヘキシルメチルアミノ)−メチル]−1H−インドール−2−イル]−2−メチル,硫酸塩(1:1),三水和物結晶が溶液から結晶化するまで該水溶液をゆっくりと加温する工程
を含む、下記式:
- 加温工程の前に、1H−イミダゾ[4,5−b]ピリジン−5−アミン,7−[5−[(シクロヘキシルメチルアミノ)−メチル]−1H−インドール−2−イル]−2−メチル,硫酸塩(1:1),三水和物結晶の種結晶を該溶液に加える工程をさらに含む、請求項7の方法。
- 該加温工程が、該溶液を2.5時間かけて70℃にゆっくり加温することを含む、請求項8の方法。
- 該加温工程が、該溶液を2.5時間かけて70℃にゆっくり加温することを含む、請求項7の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64870105P | 2005-02-02 | 2005-02-02 | |
US60/648,701 | 2005-02-02 | ||
PCT/US2006/003463 WO2006083908A1 (en) | 2005-02-02 | 2006-02-01 | Crystalline 1h-imidazo[4,5-b]pyridin-5-amine,7-[5-[(cyclohexylmethylamino)-methyl]-1h-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its pharmaceutical uses |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2008528690A JP2008528690A (ja) | 2008-07-31 |
JP2008528690A5 JP2008528690A5 (ja) | 2009-02-05 |
JP5042861B2 true JP5042861B2 (ja) | 2012-10-03 |
Family
ID=36250933
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007554170A Expired - Fee Related JP5042861B2 (ja) | 2005-02-02 | 2006-02-01 | 結晶性1H−イミダゾ[4,5−b]ピリジン−5−アミン,7−[5−[(シクロヘキシルメチルアミノ)−メチル]−1H−インドール−2−イル]−2−メチル,硫酸塩(1:1),三水和物およびその医薬的使用 |
Country Status (11)
Country | Link |
---|---|
US (1) | US7655800B2 (ja) |
EP (1) | EP1846404A1 (ja) |
JP (1) | JP5042861B2 (ja) |
KR (1) | KR101285050B1 (ja) |
CN (1) | CN101111495B (ja) |
AU (1) | AU2006210810B2 (ja) |
CA (1) | CA2596754C (ja) |
IL (1) | IL184781A (ja) |
MY (1) | MY144541A (ja) |
TW (1) | TWI378929B (ja) |
WO (1) | WO2006083908A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60305446T4 (de) * | 2002-01-07 | 2009-07-09 | Eisai R&D Management Co., Ltd. | Desazapurine und deren verwendung |
TW201613888A (en) | 2014-09-26 | 2016-04-16 | Helsinn Healthcare Sa | Crystalline forms of an NK-1 antagonist |
CN105885829B (zh) * | 2016-04-22 | 2018-05-04 | 南京工业大学 | 一种咪唑银配合物的多色发光的荧光晶体材料的制备方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7214540B2 (en) * | 1999-04-06 | 2007-05-08 | Uab Research Foundation | Method for screening crystallization conditions in solution crystal growth |
US6630006B2 (en) * | 1999-06-18 | 2003-10-07 | The Regents Of The University Of California | Method for screening microcrystallizations for crystal formation |
US7052545B2 (en) * | 2001-04-06 | 2006-05-30 | California Institute Of Technology | High throughput screening of crystallization of materials |
US7195670B2 (en) * | 2000-06-27 | 2007-03-27 | California Institute Of Technology | High throughput screening of crystallization of materials |
WO2002042731A2 (en) * | 2000-11-20 | 2002-05-30 | Parallel Synthesis Technologies, Inc. | Methods and devices for high throughput crystallization |
TWI322807B (en) | 2002-01-07 | 2010-04-01 | Eisai R&D Man Co Ltd | Novel deazapurines and uses thereof |
DE60305446T4 (de) * | 2002-01-07 | 2009-07-09 | Eisai R&D Management Co., Ltd. | Desazapurine und deren verwendung |
US6860940B2 (en) * | 2002-02-11 | 2005-03-01 | The Regents Of The University Of California | Automated macromolecular crystallization screening |
-
2006
- 2006-02-01 EP EP06720023A patent/EP1846404A1/en not_active Withdrawn
- 2006-02-01 CN CN2006800035856A patent/CN101111495B/zh not_active Expired - Fee Related
- 2006-02-01 CA CA2596754A patent/CA2596754C/en not_active Expired - Fee Related
- 2006-02-01 KR KR1020077019970A patent/KR101285050B1/ko not_active IP Right Cessation
- 2006-02-01 WO PCT/US2006/003463 patent/WO2006083908A1/en active Application Filing
- 2006-02-01 JP JP2007554170A patent/JP5042861B2/ja not_active Expired - Fee Related
- 2006-02-01 US US11/344,534 patent/US7655800B2/en not_active Expired - Fee Related
- 2006-02-01 AU AU2006210810A patent/AU2006210810B2/en not_active Ceased
- 2006-02-03 TW TW095103748A patent/TWI378929B/zh not_active IP Right Cessation
- 2006-02-03 MY MYPI20060443A patent/MY144541A/en unknown
-
2007
- 2007-07-23 IL IL184781A patent/IL184781A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
IL184781A (en) | 2012-03-29 |
AU2006210810A1 (en) | 2006-08-10 |
MY144541A (en) | 2011-09-30 |
CN101111495A (zh) | 2008-01-23 |
AU2006210810B2 (en) | 2012-03-08 |
US20060194833A1 (en) | 2006-08-31 |
US7655800B2 (en) | 2010-02-02 |
CA2596754C (en) | 2013-09-03 |
TWI378929B (en) | 2012-12-11 |
IL184781A0 (en) | 2007-12-03 |
EP1846404A1 (en) | 2007-10-24 |
WO2006083908A1 (en) | 2006-08-10 |
TW200639174A (en) | 2006-11-16 |
CN101111495B (zh) | 2011-06-15 |
JP2008528690A (ja) | 2008-07-31 |
KR101285050B1 (ko) | 2013-07-15 |
KR20070102724A (ko) | 2007-10-19 |
CA2596754A1 (en) | 2006-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021523918A (ja) | Tlr7/tlr8阻害剤の結晶形態 | |
WO2018059556A1 (zh) | 激酶抑制剂化合物的多晶型、含其的药物组合物及其制备方法和应用 | |
WO2001080857A9 (en) | Zolpidem hemitartrate | |
AU2001257213A1 (en) | Zolpidem hemitartrate | |
WO2016090257A1 (en) | Salts and crystalline forms of 6-acetyl-8-cyclopentyl-5-methyl-2((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d] pyrimidin-7(8h)-one (palbociclib) | |
JP2022000451A (ja) | ピリジノイルピペリジン5−ht1fアゴニストに関する組成物および方法 | |
JP2023532787A (ja) | 結晶形態のウパダシチニブ(upadacitinib)、その調製方法及びその使用 | |
JP5042861B2 (ja) | 結晶性1H−イミダゾ[4,5−b]ピリジン−5−アミン,7−[5−[(シクロヘキシルメチルアミノ)−メチル]−1H−インドール−2−イル]−2−メチル,硫酸塩(1:1),三水和物およびその医薬的使用 | |
JP2021523120A (ja) | セルデュラチニブ(cerdulatinib)の固体形態 | |
AU2022290823A1 (en) | New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide | |
JP2019518008A (ja) | ナトリウム−グルコース結合輸送体阻害剤のアミン溶媒和物、その調製方法およびその適用 | |
TW202227406A (zh) | Ssao抑制劑之多晶型 | |
JP2021533111A (ja) | Lta4h阻害剤の結晶形態 | |
JP2008540449A (ja) | (2e,4s)−4−[(n−{[(2r)−1−イソプロピルピペリジン−2−イル]−カルボニル}−3−メチル−l−バリル)(メチル)アミノ]−2,5−ジメチルヘキサ−2−エン酸の非溶媒和およびホストゲスト溶媒和結晶フォーム、およびそれらの医薬的使用 | |
EP4222148A1 (en) | Crystalline form of tegavivint, method of preparation, and use thereof | |
WO2019072130A1 (zh) | 一种1,2,4-三氮唑类化合物 | |
WO2022224269A1 (en) | Co-crystals, salts and solid forms of niraparib | |
WO2020222190A1 (en) | Crystalline form of 6-[4-[1 -(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1 -yl]-n-(pyrdin-4-yl)pyridine-2-carboxamide | |
WO2020222189A1 (en) | Crystalline form of 6-[4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl]-n-(pyrdin-4-yl)pyridine-2-carboxamide | |
EP1600159A1 (en) | A method for synthesizing different Zolpidem hemitartrate derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20080425 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080425 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081211 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20081211 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111220 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120216 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120313 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120511 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120612 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120711 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150720 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |